Sugi Predict

Sugi Predict / Compounds / SCHEMBL3326784

SCHEMBL3326784

SCHEMBL3326784

CCOc1ncc(F)c(Nc2n[nH]c3c2CN(C(=O)N2C[C@]4(C)CCCN4C[C@@H]2C)C3(C)C)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ PRKCB P05771 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327178 0.87 PRKCB (1.00) PRKCB
SCHEMBL16627166 0.85 PRKCB (1.00) PRKCB
SCHEMBL7015843 0.85 PRKCB (1.00) PRKCB
SCHEMBL2881453 0.85 PRKCB (1.00) PRKCB
SCHEMBL23140440 0.85 PRKCB (1.00) PRKCB
SCHEMBL3326711 0.85 PRKCB (0.89) PRKCB
SCHEMBL19200827 0.84 PRKCB (1.00) PRKCB
SCHEMBL3323117 0.84 PRKCB (1.00) PRKCB
SCHEMBL19200662 0.83 PRKCB (0.82) PRKCB
SCHEMBL19201032 0.82 PRKCB (0.82) PRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877761-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER INC. (US) 2014-11-04 — — US claimed
US-11780853-B2 Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors PFIZER INC. (US) 2023-10-10 — — US disclosed
US-11780853-B2 Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors PFIZER INC. (US) 2023-10-10 — — US disclosed
US-20230099852-A1 TREATMENT OF AUTOIMMUNE DISEASE MINGSIGHT PHARMACEUTICALS INC (US) 2023-03-30 — — US disclosed
CN-115381832-A Treatment of cancer 深圳明赛瑞霖药业有限公司 2022-11-25 — — CN disclosed
US-20220202815-A1 TREATMENT OF CANCER MINGSIGHT PHARMACEUTICALS, INC. 2022-06-30 — — US disclosed
US-20220202814-A1 TREATMENT OF CANCER MINGSIGHT PHARMACEUTICALS, INC. 2022-06-30 — — US disclosed
US-20220089613-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2022-03-24 — — US disclosed
US-20220089613-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2022-03-24 — — US disclosed
US-11220518-B2 Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors PFIZER INC. (US) 2022-01-11 — — US disclosed
US-8877761-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER INC. (US) 2014-11-04 — — US disclosed
US-8877761-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER INC. (US) 2014-11-04 — — US disclosed
US-20120202809-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PFIZER INC. 2012-08-09 — — US disclosed
US-8183255-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER, INC. (US) 2012-05-22 — — US disclosed
US-8183255-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER, INC. (US) 2012-05-22 — — US disclosed
US-8183255-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER, INC. (US) 2012-05-22 — — US disclosed
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-05-27 — — US disclosed
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-05-27 — — US disclosed
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-05-27 — — US disclosed
WO-2008096260-A1 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS PFIZER INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780853-B2 Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors PRKCB, PRKCA, PRKCQ PRKCB 1/4885
US-20220202814-A1 TREATMENT OF CANCER PRKACB, PRKDC, PRKCH PRKCB 4/4885
US-20220202815-A1 TREATMENT OF CANCER PRKACB, PRKDC, PRKCH PRKCB 4/4885
US-11220518-B2 Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors JAK3, PRKCB, PRKCA PRKCB 2/4885
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES DPP3, IAPP, GPR119 PRKCB 990/4885
US-20220089613-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES INSR, IAPP, GPR119 PRKCB 1116/4885
US-20230099852-A1 TREATMENT OF AUTOIMMUNE DISEASE PRKACB, PRKACG, PRKACA PRKCB 8/4885
US-20120202809-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PRKCB, PRKCA, PRKCE PRKCB 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.